Project Grant R01HL188033
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $836K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $1.6 million under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate GA12-dependent mechanisms of basal and regulated endothelial cell von Willebrand factor (VWF) secretion. This is a Project Grant (R01HL186410). The research addresses microvascular thrombotic occlusions in inflammatory conditions such as sepsis and sickle cell disease, where elevated VWF plasma levels...
- The National Heart, Lung, and Blood Institute awarded Yale University $577,016 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to support research into the molecular mechanisms underlying endothelial von Willebrand factor exocytosis. The research addresses how von Willebrand factor (VWF), a multifunctional plasma glycoprotein essential to hemostasis and thrombosis, is mobilized from vascular stores in endothelial cells. VWF is synthesized and stored in...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $248,967 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research dissecting vascular reperfusion and remodeling after injury in zebrafish models. The award funds investigation into how delayed vascular reperfusion contributes to chronic, non-healing wounds affecting approximately two percent of the U.S. population. The research examines molecular mechanisms...
- The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded $743,131 to the University of Wisconsin - Madison on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory mechanisms of the vessel wall in deep vein thrombosis. The research addresses thrombospondin-1 (TSP1), a matricellular protein upregulated in endothelial cells during DVT. The project tests...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $1,626,320 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study thrombotic disorders linked by ADAMTS13 deficiency. The research investigates the metalloprotease ADAMTS13, which cleaves ultra-large von Willebrand factor multimers into smaller units and regulates the thrombogenicity of this circulating coagulation factor. The project focuses on immune...
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Bloodworks $724,351 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate the mechanisms by which extracellular mitochondria released from traumatic brain injury sites cause endothelial cell injury and contribute to hemostatic dysfunction and coagulopathy. The research addresses a gap in understanding subcellular changes in endothelial cell injury during traumatic...
- The National Heart Lung and Blood Institute awarded North Carolina State University $698,083 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop hemostatic B-knob triggered microgels that leverage age-dependent clotting mechanisms for treating pediatric trauma-associated hemorrhage. The project addresses life-threatening bleeding in pediatric trauma patients, where hemorrhagic shock is a common cause of death. Current treatment relies on...
- The National Heart, Lung, and Blood Institute awarded Versiti Blood Health, Inc. $1,069,072 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode kindlin-3 signaling in platelets and neutrophils. The research investigates the regulatory role of kindlin-3, a critical signaling adaptor in hematopoietic cells, in thrombosis and inflammation. The project focuses on elucidating molecular mechanisms by which kindlin-3 regulates platelet activation during...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $539,066 to Massachusetts General Hospital (The General Hospital Corporation, Research Management Division) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating the role of microglial extracellular vesicles in the progression of atherosclerosis following traumatic brain injury. The...